glp-1 receptor agonists in pediatric and adolescent obesity prescribing among teens with GLP‐1 Agonists for Pediatric Psychopharmacology:
Description
Common side effects tend to be mild and go away the longer you are on the medication
Gupta NA, Kolachala VL, Jiang R, Abramowsky C, Romero R, Fifadara N, et al
Gromada, J., Holst, J
A number of studies dedicated to GLP-1RA efficacy in T2D included patients with chronic HF (CHF) (16.2% in the EXSCEL trial, 23.6% in SUSTAIN-6, 12.2% in PIONEER, 8.6% in REWIND, 20% in Harmony, 22% in ELIXA and 18% in LEADER)
They believed it differed from pancreozymin, another small intestine hormone identified by Ivy in 1928 that was subsequently renamed cholecystokinin (CCK) (Kosaka, Lim)
